Skip to main content

Athira Pharma, Inc. (ATHA)

NASDAQ: ATHA · IEX Real-Time Price · USD
9.61 -0.33 (-3.35%)
Sep 24, 2021 2:14 PM EDT - Market open
Market Cap368.86M
Revenue (ttm)n/a
Net Income (ttm)-39.00M
Shares Out37.30M
EPS (ttm)-1.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume149,837
Open9.92
Previous Close9.94
Day's Range9.58 - 9.95
52-Week Range8.88 - 34.79
Betan/a
AnalystsBuy
Price Target39.50 (+311.2%)
Est. Earnings DateNov 11, 2021

About ATHA

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, inc...

IndustryBiotechnology
IPO DateSep 18, 2020
Employees20
Stock ExchangeNASDAQ
Ticker SymbolATHA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Athira Pharma stock is "Buy." The 12-month stock price forecast is 39.50, which is an increase of 311.16% from the latest price.

Price Target
$39.50
(311.16% upside)
Analyst Consensus: Buy

News

Athira Pharma, Inc. (ATHA) Dips More Than Broader Markets: What You Should Know

Athira Pharma, Inc. (ATHA) closed at $10.13 in the latest trading session, marking a -1.65% move from the prior day.

6 days ago - Zacks Investment Research

Athira Shareholder Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp....

3 weeks ago - Newsfile Corp

Last Day for Shareholders to Actively Participate in Athira Pharma, Inc. (ATHA) Class Action: Bronstein, Gewirtz & Gr...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athira Pharma, Inc. ("Athira " or "the Company")...

1 month ago - Business Wire

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and En...

Los Angeles, California--(Newsfile Corp. - August 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, In...

1 month ago - Newsfile Corp

ATHA DEADLINE TODAY: Hagens Berman Encourages Athira Pharma (ATHA) Investors with Losses to Contact Firm's Attorneys ...

San Francisco, California--(Newsfile Corp. - August 24, 2021) -  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class ac...

1 month ago - Newsfile Corp

Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Athira Pharma, Inc. Investors – ATHA

RANDOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuits have been filed against Athira Pharma, Inc. (NASDAQ: ATHA) ...

1 month ago - Business Wire

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and...

Los Angeles, California--(Newsfile Corp. - August 23, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, In...

1 month ago - Newsfile Corp

Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alz...

BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...

1 month ago - GlobeNewsWire

FINAL DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before ...

New York, New York--(Newsfile Corp. - August 23, 2021) - WHY: New York, N.Y., August 22, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, I...

1 month ago - Newsfile Corp

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pha...

LOS ANGELES--(BUSINESS WIRE)---- $ATHA #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)

1 month ago - Business Wire

Athira Class Action Reminder

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp....

1 month ago - Newsfile Corp

FINAL NOTICE: Investors with Substantial Losses Have Opportunity to Lead the Athira Pharma, Inc. Class Action Lawsuit...

SAN DIEGO, Aug. 21, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Athira Pharma, Inc. (NASDAQ: ATHA) securities between September 18, 2020 and June 17, 2021, inclusi...

1 month ago - PRNewsWire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athira Pharma, Inc. (...

LOS ANGELES, Aug. 20, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired At...

1 month ago - PRNewsWire

TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, In...

Los Angeles, California--(Newsfile Corp. - August 20, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, In...

1 month ago - Newsfile Corp

ATHIRA PHARMA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with L...

New Orleans, Louisiana--(Newsfile Corp. - August 19, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have u...

1 month ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athira Pharma, Inc. - ATHA

NEW YORK, Aug. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of. Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA).

1 month ago - PRNewsWire

Athira Shareholder Alert

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp....

1 month ago - Newsfile Corp

FINAL DEADLINE NOTICE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athira Pharma, Inc. Investors With Losse...

New York, New York--(Newsfile Corp. - August 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant ...

1 month ago - Newsfile Corp

TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, ...

Los Angeles, California--(Newsfile Corp. - August 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, In...

1 month ago - Newsfile Corp

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit A...

BENSALEM, Pa. – ­­, Aug. 18, 2021 /PRNewswire/ -- Law Offices of Howard G.

1 month ago - PRNewsWire

TUESDAY DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Athira Pharma, Inc. Class Action Law...

SAN DIEGO--(BUSINESS WIRE)-- #ATHAstock--The suit alleges defendants issued false statements concerning Athira business and prospects, resulting in its stock trading at inflated prices.

1 month ago - Business Wire

Final Deadline Approaching on August 24, 2021: Kessler Topaz Meltzer & Check, LLP Reminds Athira Pharma, Inc. Investo...

Radnor, Pennsylvania--(Newsfile Corp. - August 17, 2021) -  The law firm of Kessler Topaz Meltzer & Check, LLP reminds Athira Pharma, Inc. (NASDAQ: ATHA) ("Athira") investors that securities fraud class...

1 month ago - Newsfile Corp

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, I...

LOS ANGELES--(BUSINESS WIRE)---- $ATHA #ATHA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc.

1 month ago - Business Wire

Athira Pharma extends Alzheimer's clinical trial, adds new execs after CEO placed on leave

Athira Pharma is advancing its clinical trials in the wake of allegations of image manipulation in papers authored by its CEO, the company reported today in its second quarter financial and business upd...

1 month ago - GeekWire

Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update

- Initiated open label extension for LIFT-AD and ACT-AD trials of ATH-1017 allowing for an additional six months of treatment

1 month ago - GlobeNewsWire